B+
Bull case
25%
Probability
Target price
$0.85
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
CUE
Cue BiopharmaFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The constructive case is that Cue preserves Nasdaq listing, avoids a disorderly financing outcome, and continues extracting non-dilutive value from collaborations such as ImmunoScape and BI, leaving the equity materially above today's distressed micro-cap level if funding pressure eases [#8-K-2026-04-13] [#10-K-2026-03-16].
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta 0.0.
What can break
Collaboration-related cash inflows, including ImmunoScape timing, may not be sufficient to offset broader funding needs [#10-K-2026-03-16].
Momentum
41
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.38 · Bull $0.85 · Bear $0.14Analysis 2026-04-15; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $90.50
Why
Momentum41 · Δ7d +19.6
Value41 · Δ7d 0.0
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta 0.0.
Contradictions & invalidation
- • Collaboration-related cash inflows, including ImmunoScape timing, may not be sufficient to offset broader funding needs [#10-K-2026-03-16].
- • High probability of future dilution or expensive capital raises given explicit going-concern language and stated need for substantial additional capital [#10-K-2026-03-16].
- • The bear case is that Nasdaq compliance requires a reverse split without improving underlying financing leverage, after which Cue still needs additional capital under a going-concern backdrop; that combination could produce further dilution, weaker liquidity, and renewed downside [#8-K-2026-04-13] [#10-K-2026-03-16].
Catalyst clock
2026-05-11
Board decision on implementing the approved reverse split before Nasdaq deadline
Lead driver: Value · See fundamentals
Momentum
41
9% active weight
Current posture
7d trendImproving
Δ7d
+19.6
Δ21d
-12.8
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
0
62% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade F. Momentum 40.6 / Value 41.2 / Sentiment 0.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-15. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$0.38
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.14
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$188.68M
Beta
1.49
Shares Out
4.2M
P/E (TTM) · Derived
-5.3
P/S (TTM)
4.24
P/FCF (TTM) · Derived
-4.56
Rev YoY
+166.7%
EPS YoY
+805.6%
Gross Margin
+99.3%
Op Margin
-262.0%
Net Debt
-$22.94M
Current Ratio
1.25
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data